Cargando…

Parkinson’s disease: carbidopa, nausea, and dyskinesia

When l-dopa use began in the early 1960s for the treatment of Parkinson’s disease, nausea and reversible dyskinesias were experienced as continuing side effects. Carbidopa or benserazide was added to l-dopa in 1975 solely to control nausea. Subsequent to the increasing use of carbidopa has been the...

Descripción completa

Detalles Bibliográficos
Autores principales: Hinz, Marty, Stein, Alvin, Cole, Ted
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4238750/
https://www.ncbi.nlm.nih.gov/pubmed/25484598
http://dx.doi.org/10.2147/CPAA.S72234
_version_ 1782345505603321856
author Hinz, Marty
Stein, Alvin
Cole, Ted
author_facet Hinz, Marty
Stein, Alvin
Cole, Ted
author_sort Hinz, Marty
collection PubMed
description When l-dopa use began in the early 1960s for the treatment of Parkinson’s disease, nausea and reversible dyskinesias were experienced as continuing side effects. Carbidopa or benserazide was added to l-dopa in 1975 solely to control nausea. Subsequent to the increasing use of carbidopa has been the recognition of irreversible dyskinesias, which have automatically been attributed to l-dopa. The research into the etiology of these phenomena has identified the causative agent of the irreversible dyskinesias as carbidopa, not l-dopa. The mechanism of action of the carbidopa and benserazide causes irreversible binding and inactivation of vitamin B(6) throughout the body. The consequences of this action are enormous, interfering with over 300 enzyme and protein functions. This has the ability to induce previously undocumented profound antihistamine dyskinesias, which have been wrongly attributed to l-dopa and may be perceived as irreversible if proper corrective action is not taken.
format Online
Article
Text
id pubmed-4238750
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-42387502014-12-05 Parkinson’s disease: carbidopa, nausea, and dyskinesia Hinz, Marty Stein, Alvin Cole, Ted Clin Pharmacol Perspectives When l-dopa use began in the early 1960s for the treatment of Parkinson’s disease, nausea and reversible dyskinesias were experienced as continuing side effects. Carbidopa or benserazide was added to l-dopa in 1975 solely to control nausea. Subsequent to the increasing use of carbidopa has been the recognition of irreversible dyskinesias, which have automatically been attributed to l-dopa. The research into the etiology of these phenomena has identified the causative agent of the irreversible dyskinesias as carbidopa, not l-dopa. The mechanism of action of the carbidopa and benserazide causes irreversible binding and inactivation of vitamin B(6) throughout the body. The consequences of this action are enormous, interfering with over 300 enzyme and protein functions. This has the ability to induce previously undocumented profound antihistamine dyskinesias, which have been wrongly attributed to l-dopa and may be perceived as irreversible if proper corrective action is not taken. Dove Medical Press 2014-11-14 /pmc/articles/PMC4238750/ /pubmed/25484598 http://dx.doi.org/10.2147/CPAA.S72234 Text en © 2014 Hinz et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Perspectives
Hinz, Marty
Stein, Alvin
Cole, Ted
Parkinson’s disease: carbidopa, nausea, and dyskinesia
title Parkinson’s disease: carbidopa, nausea, and dyskinesia
title_full Parkinson’s disease: carbidopa, nausea, and dyskinesia
title_fullStr Parkinson’s disease: carbidopa, nausea, and dyskinesia
title_full_unstemmed Parkinson’s disease: carbidopa, nausea, and dyskinesia
title_short Parkinson’s disease: carbidopa, nausea, and dyskinesia
title_sort parkinson’s disease: carbidopa, nausea, and dyskinesia
topic Perspectives
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4238750/
https://www.ncbi.nlm.nih.gov/pubmed/25484598
http://dx.doi.org/10.2147/CPAA.S72234
work_keys_str_mv AT hinzmarty parkinsonsdiseasecarbidopanauseaanddyskinesia
AT steinalvin parkinsonsdiseasecarbidopanauseaanddyskinesia
AT coleted parkinsonsdiseasecarbidopanauseaanddyskinesia